Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Change in Accured Expenses: 2016-2025

Historic Change in Accured Expenses for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to $11.0 million.

  • Rhythm Pharmaceuticals' Change in Accured Expenses rose 46.71% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.8 million, marking a year-over-year increase of 208.84%. This contributed to the annual value of $21.9 million for FY2024, which is 48.37% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Change in Accured Expenses stood at $11.0 million for Q3 2025, which was down 16.90% from $13.3 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Change in Accured Expenses ranged from a high of $15.7 million in Q4 2022 and a low of -$12.6 million during Q3 2022.
  • For the 3-year period, Rhythm Pharmaceuticals' Change in Accured Expenses averaged around $5.2 million, with its median value being $4.9 million (2023).
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Change in Accured Expenses tumbled by 309.83% in 2022, and later soared by 9,849.06% in 2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at $12.9 million in 2021, then rose by 21.61% to $15.7 million in 2022, then plummeted by 69.08% to $4.9 million in 2023, then skyrocketed by 212.45% to $15.2 million in 2024, then spiked by 46.71% to $11.0 million in 2025.
  • Its Change in Accured Expenses stands at $11.0 million for Q3 2025, versus $13.3 million for Q2 2025 and -$3.6 million for Q1 2025.